Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?

Author Information
Article Notes and Dates
To Cite : Tarantino G. Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?, Hepat Mon. 2013 ;13(2):e7560. doi: 10.5812/hepatmon.7560.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Footnotes
References
  • 1. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011; 364(25): 2392-404[DOI][PubMed]
  • 2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115(2): 209-18[DOI][PubMed]
  • 3. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59(7): 969-74[DOI][PubMed]
  • 4. Bosserhoff A, Hellerbrand C. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis. Dig Dis. 2011; 29(4): 377-83[DOI][PubMed]
  • 5. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008; 6: 72[DOI][PubMed]
  • 6. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995; 346(8981): 987-90[PubMed]
  • 7. Tarantino G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J Gastroenterol. 2007; 13(35): 4669-72[PubMed]
  • 8. Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, et al. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond). 2009; 6: 6[DOI][PubMed]
  • 9. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22): 2297-307[DOI][PubMed]
  • 10. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18): 1675-85[DOI][PubMed]
  • 11. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16): 1659-68[DOI][PubMed]
  • 12. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012; 35(1): 66-75[DOI][PubMed]
  • 13. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012; 35(1): 76-82[DOI][PubMed]
  • 14. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011; 53(3): 810-20[DOI][PubMed]
  • 15. Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther. 2011; 34(2): 214-8[DOI][PubMed]
  • 16. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011; 53(6): 1874-82[DOI][PubMed]
  • 17. Lee KH, Park SH, Kim YJ, Huh KR, Min KS, Jun SY, et al. [Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors]. Korean J Hepatol. 2010; 16(1): 29-37[DOI][PubMed]
  • 18. Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011; 45(1): 55-8[DOI][PubMed]
  • 19. Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One. 2008; 3(12)[DOI][PubMed]
  • 20. Mori M, Fujii H, Ogawa T, Kobayashi S, Iwai S, Morikawa H, et al. Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. Hepatol Res. 2011; 41(9): 897-903[DOI][PubMed]
  • 21. Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther. 2011; 33(12): 1350-60[DOI][PubMed]
  • 22. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012; 61(3): 409-15[DOI][PubMed]
  • 23. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012; 12: 2[DOI][PubMed]
  • 24. Blomme B, Francque S, Trepo E, Libbrecht L, Vanderschaeghe D, Verrijken A, et al. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis. 2012; 44(4): 315-22[DOI][PubMed]
  • 25. Hamman RF, Halil T, Holland WW. Asthma in schoolchildren. Demographic associations and peak expiratory flow rates compared in children with bronchitis. Br J Prev Soc Med. 1975; 29(4): 228-38[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check